+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lung Cancer Screening Software Market - Global Forecast 2026-2032- Product Image
Lung Cancer Screening Software Market - Global Forecast 2026-2032- Product Image
Sale

Lung Cancer Screening Software Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6090365
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Lung Cancer Screening Software Market is projected to reach USD 3.20 Billion in 2026. It is expected to continue growing at a CAGR of 6.93%, reaching USD 4.80 Billion by 2032.

Lung Cancer Screening Software: Executive Overview

Lung cancer screening software supports the identification, review, prioritization, and documentation of findings from screening imaging, particularly low-dose computed tomography. Its role is expanding as health systems seek more consistent nodule assessment, efficient radiology workflows, and stronger links between screening, follow-up, and clinical care. Adoption depends on clinical validation, interoperability, regulatory alignment, cybersecurity, and the ability to fit existing screening pathways without increasing unnecessary procedures or inequitable access.

Workflow Integration Is Reshaping Screening Delivery

Screening programs are moving from isolated image interpretation toward coordinated pathways that connect eligibility assessment, imaging acquisition, automated or assisted analysis, radiologist review, longitudinal nodule tracking, referral, and follow-up. This shift increases the value of software that can reduce repetitive work while preserving clinician oversight and transparent documentation. Successful deployment also requires standardized protocols, clear escalation rules, quality monitoring, and integration with electronic health records, radiology information systems, and picture archiving environments.

Artificial Intelligence Strengthens Detection and Prioritization

Artificial intelligence is being applied to nodule detection, segmentation, malignancy-risk assessment, comparison of prior examinations, and worklist prioritization. Its cumulative impact is greatest when it complements radiologists rather than functioning as an opaque replacement for judgment. Evidence generation must address sensitivity, false-positive control, model drift, subgroup performance, incidental findings, and the consequences of automation bias. Human review, explainable outputs, audit trails, and continuous post-deployment monitoring remain essential for safe clinical use.

Regional Differences Shape Adoption and Program Design

North America benefits from established screening guidelines, advanced imaging infrastructure, and comparatively mature digital integration, while implementation still varies by eligibility, reimbursement, and rural access. Europe is shaped by national health-system structures, data-governance requirements, multilingual workflows, and uneven program maturity across the European Union. Asia-Pacific combines advanced markets such as Australia, Japan, and South Korea with rapidly expanding but heterogeneous systems, including China and India. Latin America faces variation in imaging capacity, referral continuity, and public-sector resources. The Middle East is influenced by centralized health initiatives, specialist concentration, and interoperability priorities, while Africa generally requires solutions that accommodate constrained equipment availability, workforce shortages, connectivity limitations, and locally appropriate screening pathways.

Cross-Group Priorities Differ Across ASEAN, BRICS, and Alliances

ASEAN countries face diverse infrastructure and regulatory environments, making interoperability, affordability, and adaptable deployment important. BRICS members span substantial differences in public-health capacity, domestic technology ecosystems, and access to specialist interpretation, favoring scalable models with strong localization. European Union systems must align with rigorous privacy, medical-device, and cross-border data requirements. G7 members generally emphasize evidence, workflow efficiency, cybersecurity, and integration with mature clinical infrastructure. GCC health systems often prioritize centralized modernization, specialist access, and coordinated screening pathways. NATO members may share high expectations for resilience, secure infrastructure, and continuity of health services, although national procurement and clinical policies remain distinct.

Country Conditions Determine Practical Deployment

Australia’s distributed population makes remote access and coordinated follow-up important. Brazil and Mexico must address regional disparities in imaging and specialist capacity. Canada and the United States have established screening frameworks but continue to face access, reimbursement, and rural-delivery challenges. China and India require approaches suited to large, diverse populations and varied institutional resources. France, Germany, Italy, Spain, and the United Kingdom operate within structured health systems where evidence, procurement, privacy, and workflow integration are central considerations. Japan and South Korea combine advanced imaging capabilities with strong interest in efficiency and aging-population care. Russia’s deployment environment is shaped by national health-system organization, infrastructure variation, and data governance. Across all countries, clinical validation in representative populations and dependable follow-up pathways are critical.

Prioritize Validated, Interoperable, and Equitable Implementations

Industry leaders should select software using prospective clinical evidence, subgroup testing, transparent performance reporting, and clear responsibility for final decisions. Deployments should begin with defined workflow problems, measurable safety and efficiency outcomes, and integration testing across imaging, reporting, records, and referral systems. Governance should include cybersecurity controls, privacy safeguards, model-change management, bias review, user training, and mechanisms for reporting adverse events or unexpected outputs. Leaders should also design for equity by supporting rural and lower-resource settings, reducing language and accessibility barriers, and linking detection tools to reliable diagnostic and treatment follow-up.

Methodology for a Reliable Executive Assessment

This executive summary uses a qualitative synthesis framework focused on documented clinical, operational, regulatory, and infrastructure factors affecting lung cancer screening software. The assessment organizes evidence across regional, country, and geopolitical-group contexts, then evaluates recurring themes including artificial intelligence, interoperability, workflow integration, safety, equity, and governance. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific comparisons. Conclusions should be interpreted alongside current clinical guidelines, regulatory decisions, peer-reviewed validation studies, health-system requirements, and local implementation evidence.

Safe Integration Will Define Long-Term Value

Lung cancer screening software is most useful when it improves consistency and coordination across the complete screening pathway rather than focusing only on image analysis. The strongest implementations will combine clinically credible artificial intelligence with radiologist oversight, interoperable infrastructure, rigorous governance, and dependable follow-up. Regional and country differences mean that deployment models must be adaptable, evidence-based, and attentive to equity. Leaders that treat software as part of a governed care system-not as a standalone algorithm-will be better positioned to improve screening quality and operational performance.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Lung Cancer Screening Software Market, by Software Type
7.1. Introduction
7.2. Integrated
7.3. Standalone
8. Lung Cancer Screening Software Market, by Lung Cancer Type
8.1. Introduction
8.2. Non-Small Cell Lung Cancer (NSCLC)
8.3. Small Cell Lung Cancer (SCLC)
9. Lung Cancer Screening Software Market, by Application
9.1. Introduction
9.2. Early Detection
9.3. Risk Assessment
9.4. Treatment Monitoring
10. Lung Cancer Screening Software Market, by End User
10.1. Introduction
10.2. Cancer Centers
10.3. Diagnostic Imaging Centers
10.4. Hospitals
10.5. Research Institutions
11. Lung Cancer Screening Software Market, by Deployment Mode
11.1. Introduction
11.2. Cloud-based
11.3. On-premise
12. Lung Cancer Screening Software Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Lung Cancer Screening Software Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Lung Cancer Screening Software Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Aidoc Medical, Ltd.
16.2. Behold.ai Limited
16.3. Canon Medical Systems Corporation
16.4. ContextVision AB
16.5. DeepHealth, Inc. by RadNet, Inc.
16.6. Enlitic, Inc.
16.7. Fujifilm Holdings Corporation
16.8. General Electric Company
16.9. Google LLC by Alphabet Inc.
16.10. Hologic, Inc.
16.11. iCAD, Inc.
16.12. Infervision Medical Technology Co., Ltd.
16.13. Koninklijke Philips N.V.
16.14. Lunit Inc.
16.15. Microsoft Corporation
16.16. NVIDIA Corporation
16.17. Optellum Ltd.
16.18. Oracle Corporation
16.19. Proscia Inc.
16.20. Qure.ai Technologies Private Limited
16.21. RadLogics, Inc.
16.22. Siemens Healthineers AG
16.23. Viz.ai, Inc.
16.24. Zebra Medical Vision Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Lung Cancer Screening Software Market, Years Considered for the Study
FIGURE 2. Global Lung Cancer Screening Software Market, Research Design
FIGURE 3. Global Lung Cancer Screening Software Market, Research Framework
FIGURE 4. Global Lung Cancer Screening Software Market, Data Triangulation
FIGURE 5. Global Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Lung Cancer Screening Software Market Size, by Software Type, 2025 vs 2032 (%)
FIGURE 7. Global Lung Cancer Screening Software Market Size, by Software Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2025 vs 2032 (%)
FIGURE 9. Global Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Lung Cancer Screening Software Market Size, by Application, 2025 vs 2032 (%)
FIGURE 11. Global Lung Cancer Screening Software Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Lung Cancer Screening Software Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Lung Cancer Screening Software Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Lung Cancer Screening Software Market Size, by Deployment Mode, 2025 vs 2032 (%)
FIGURE 15. Global Lung Cancer Screening Software Market Size, by Deployment Mode, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Lung Cancer Screening Software Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Lung Cancer Screening Software Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Lung Cancer Screening Software Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Lung Cancer Screening Software Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Lung Cancer Screening Software Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Lung Cancer Screening Software Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Lung Cancer Screening Software Market Segmentation & Coverage
TABLE 2. Global Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 3. Global Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 4. Global Integrated Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Integrated Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Integrated Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Standalone Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Standalone Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Standalone Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 11. Global Non-Small Cell Lung Cancer (NSCLC) Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Non-Small Cell Lung Cancer (NSCLC) Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Non-Small Cell Lung Cancer (NSCLC) Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Small Cell Lung Cancer (SCLC) Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Small Cell Lung Cancer (SCLC) Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Small Cell Lung Cancer (SCLC) Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 18. Global Early Detection Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Early Detection Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Early Detection Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Risk Assessment Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Risk Assessment Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Risk Assessment Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Treatment Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Treatment Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Treatment Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 28. Global Cancer Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Cancer Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Cancer Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Diagnostic Imaging Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Diagnostic Imaging Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Diagnostic Imaging Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Research Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Research Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Research Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 41. Global Cloud-based Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Cloud-based Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Cloud-based Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global On-premise Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global On-premise Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global On-premise Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Lung Cancer Screening Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Asia-Pacific Lung Cancer Screening Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Asia-Pacific Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 54. North America Lung Cancer Screening Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. North America Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 56. North America Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 57. North America Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 58. North America Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 59. North America Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 60. Latin America Lung Cancer Screening Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Latin America Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 62. Latin America Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 63. Latin America Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 64. Latin America Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. Latin America Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 66. Europe Lung Cancer Screening Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Europe Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 68. Europe Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 69. Europe Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 70. Europe Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Europe Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 72. Middle East Lung Cancer Screening Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Middle East Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 74. Middle East Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 75. Middle East Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 76. Middle East Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. Middle East Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 78. Africa Lung Cancer Screening Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Africa Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 80. Africa Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 81. Africa Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 82. Africa Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Africa Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 84. Global Lung Cancer Screening Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. ASEAN Lung Cancer Screening Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. ASEAN Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 87. ASEAN Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 88. ASEAN Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 89. ASEAN Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. ASEAN Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 91. GCC Lung Cancer Screening Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. GCC Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 93. GCC Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 94. GCC Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 95. GCC Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. GCC Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 97. European Union Lung Cancer Screening Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. European Union Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 99. European Union Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 100. European Union Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 101. European Union Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. European Union Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 103. BRICS Lung Cancer Screening Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. BRICS Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 105. BRICS Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 106. BRICS Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 107. BRICS Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. BRICS Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 109. G7 Lung Cancer Screening Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. G7 Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 111. G7 Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 112. G7 Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 113. G7 Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. G7 Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 115. NATO Lung Cancer Screening Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. NATO Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 117. NATO Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 118. NATO Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 119. NATO Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. NATO Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 121. Global Lung Cancer Screening Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. United States Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 123. United States Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 124. United States Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 125. United States Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 126. United States Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. United States Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 128. Canada Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 129. Canada Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 130. Canada Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 131. Canada Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 132. Canada Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. Canada Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 134. Mexico Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 135. Mexico Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 136. Mexico Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 137. Mexico Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 138. Mexico Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. Mexico Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 140. Brazil Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 141. Brazil Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 142. Brazil Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 143. Brazil Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 144. Brazil Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Brazil Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 146. United Kingdom Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 147. United Kingdom Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 148. United Kingdom Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 149. United Kingdom Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 150. United Kingdom Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. United Kingdom Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 152. Germany Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 153. Germany Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 154. Germany Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 155. Germany Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 156. Germany Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Germany Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 158. France Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 159. France Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 160. France Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 161. France Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 162. France Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. France Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 164. Russia Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 165. Russia Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 166. Russia Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 167. Russia Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 168. Russia Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Russia Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 170. Italy Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 171. Italy Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 172. Italy Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 173. Italy Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 174. Italy Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Italy Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 176. Spain Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 177. Spain Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 178. Spain Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 179. Spain Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 180. Spain Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Spain Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 182. China Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 183. China Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 184. China Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 185. China Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 186. China Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. China Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 188. India Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 189. India Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 190. India Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 191. India Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 192. India Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. India Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 194. Japan Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 195. Japan Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 196. Japan Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 197. Japan Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 198. Japan Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Japan Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 200. Australia Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 201. Australia Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 202. Australia Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 203. Australia Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 204. Australia Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Australia Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 206. South Korea Lung Cancer Screening Software Market Size, 2017-2032 (USD Million)
TABLE 207. South Korea Lung Cancer Screening Software Market Size, by Software Type, 2017-2032 (USD Million)
TABLE 208. South Korea Lung Cancer Screening Software Market Size, by Lung Cancer Type, 2017-2032 (USD Million)
TABLE 209. South Korea Lung Cancer Screening Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 210. South Korea Lung Cancer Screening Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. South Korea Lung Cancer Screening Software Market Size, by Deployment Mode, 2017-2032 (USD Million)
TABLE 212. Global Lung Cancer Screening Software Market Share, by Key Player, 2025
TABLE 213. Global Lung Cancer Screening Software Market, Key Experts

Companies Mentioned

  • Aidoc Medical, Ltd.
  • Behold.ai Limited
  • Canon Medical Systems Corporation
  • ContextVision AB
  • DeepHealth, Inc. by RadNet, Inc.
  • Enlitic, Inc.
  • Fujifilm Holdings Corporation
  • General Electric Company
  • Google LLC by Alphabet Inc.
  • Hologic, Inc.
  • iCAD, Inc.
  • Infervision Medical Technology Co., Ltd.
  • Koninklijke Philips N.V.
  • Lunit Inc.
  • Microsoft Corporation
  • NVIDIA Corporation
  • Optellum Ltd.
  • Oracle Corporation
  • Proscia Inc.
  • Qure.ai Technologies Private Limited
  • RadLogics, Inc.
  • Siemens Healthineers AG
  • Viz.ai, Inc.
  • Zebra Medical Vision Ltd.

Related Topics

Related Reports

Cancer Screening Vehicles Market - Global Forecast 2026-2032 - Product Image

Cancer Screening Vehicles Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Lung Cancer Screening Software - Global Strategic Business Report - Product Image

Lung Cancer Screening Software - Global Strategic Business Report

  • Report
  • 98 Pages
  • Global
From
Lung Cancer Screening Software Market Outlook 2026-2034: Market Share and Growth Analysis by Mode (of Delivery, Cloud-based Solutions, On-premise Solutions, Web-based Solutions), Product, End User - Product Image

Lung Cancer Screening Software Market Outlook 2026-2034: Market Share and Growth Analysis by Mode (of Delivery, Cloud-based Solutions, On-premise Solutions, Web-based Solutions), Product, End User

  • Report
  • 160 Pages
  • Global
From
Lung Cancer Diagnostic and Screening Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Lung Cancer Diagnostic and Screening Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Lung Cancer Screening Software Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Lung Cancer Screening Software Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.